Published in Radiology on September 01, 2008
Predicting and monitoring cancer treatment response with diffusion-weighted MRI. J Magn Reson Imaging (2010) 1.82
Predictive value of diffusion-weighted magnetic resonance imaging during chemoradiotherapy for head and neck squamous cell carcinoma. Eur Radiol (2010) 1.42
Magnetic resonance in the era of molecular imaging of cancer. Magn Reson Imaging (2011) 1.08
DCE-MRI detects early vascular response in breast tumor xenografts following anti-DR5 therapy. Mol Imaging Biol (2011) 1.07
Treatment of arthritis by macrophage depletion and immunomodulation: testing an apoptosis-mediated therapy in a humanized death receptor mouse model. Arthritis Rheum (2011) 1.03
Dual combination therapy targeting DR5 and EMMPRIN in pancreatic adenocarcinoma. Mol Cancer Ther (2011) 0.97
Extended morphological processing: a practical method for automatic spot detection of biological markers from microscopic images. BMC Bioinformatics (2010) 0.96
Noninvasive monitoring of HPMA copolymer-RGDfK conjugates by magnetic resonance imaging. Pharm Res (2009) 0.91
Extracelluar matrix metalloproteinase as a novel target for pancreatic cancer therapy. Anticancer Drugs (2011) 0.89
Antagonistic effects of anti-EMMPRIN antibody when combined with chemotherapy against hypovascular pancreatic cancers. Mol Imaging Biol (2013) 0.82
Early therapy assessment of combined anti-DR5 antibody and carboplatin in triple-negative breast cancer xenografts in mice using diffusion-weighted imaging and (1)H MR spectroscopy. J Magn Reson Imaging (2013) 0.82
High-field small animal magnetic resonance oncology studies. Phys Med Biol (2013) 0.81
Volumetric contrast-enhanced ultrasound imaging to assess early response to apoptosis-inducing anti-death receptor 5 antibody therapy in a breast cancer animal model. J Ultrasound Med (2012) 0.81
New targets for the treatment of follicular lymphoma. J Hematol Oncol (2009) 0.80
Translational pathology of neoplasia. Cancer Biomark (2010) 0.79
Diffusion-weighted MRI for imaging cell death after cytotoxic or apoptosis-inducing therapy. Br J Cancer (2015) 0.79
Role of quantitative magnetic resonance imaging parameters in the evaluation of treatment response in malignant tumors. Chin Med J (Engl) (2015) 0.79
Monitoring the development of xenograft triple-negative breast cancer models using diffusion-weighted magnetic resonance imaging. Exp Biol Med (Maywood) (2012) 0.78
Experimental study of nasopharyngeal carcinoma radionuclide imaging and therapy using transferred human sodium/iodide symporter gene. PLoS One (2015) 0.77
Chemotherapy response evaluation in a mouse model of gastric cancer using intravoxel incoherent motion diffusion-weighted MRI and histopathology. World J Gastroenterol (2017) 0.75
Monitoring the Effect of Docetaxel Treatment in MCF7 Xenografts Using Multimodal In Vivo and Ex Vivo Magnetic Resonance Methods, Histopathology, and Gene Expression. Transl Oncol (2010) 0.75
Combination therapy with anti-DR5 antibody and tamoxifen for triple negative breast cancer. Cancer Biol Ther (2014) 0.75
Diffusion weighted imaging evaluated the early therapy effect of tamoxifen in an MNU-induced mammary cancer rat model. PLoS One (2013) 0.75
Perfusion parameters as potential imaging biomarkers for the early prediction of radiotherapy response in a rat tumor model. Diagn Interv Radiol (2016) 0.75
Molecular imaging metrics to evaluate response to preclinical therapeutic regimens. Front Biosci (Landmark Ed) (2011) 0.75
Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med (1999) 9.78
Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest (1999) 7.69
Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science (1997) 6.82
The receptor for the cytotoxic ligand TRAIL. Science (1997) 6.39
An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science (1997) 6.10
Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. J Natl Cancer Inst (2000) 5.14
Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med (2000) 4.40
TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J (1997) 4.28
Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat Med (2007) 3.99
Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem (1998) 3.88
Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway. Immunity (1997) 3.33
The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity (1997) 3.11
Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med (2001) 2.87
TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB. Immunity (1997) 2.60
Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proc Natl Acad Sci U S A (2000) 2.49
Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J Exp Med (1997) 2.46
A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proc Natl Acad Sci U S A (2006) 2.36
Early increases in breast tumor xenograft water mobility in response to paclitaxel therapy detected by non-invasive diffusion magnetic resonance imaging. Neoplasia (1999) 2.24
Diffusion-weighted and perfusion MR imaging for brain tumor characterization and assessment of treatment response. Radiology (2006) 2.10
Diffusion-weighted imaging of malignant breast tumors: the usefulness of apparent diffusion coefficient (ADC) value and ADC map for the detection of malignant breast tumors and evaluation of cancer extension. J Comput Assist Tomogr (2005) 2.05
ADC mapping of benign and malignant breast tumors. Magn Reson Med Sci (2005) 2.02
Quantitative diffusion imaging in breast cancer: a clinical prospective study. J Magn Reson Imaging (2006) 2.00
Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model. Clin Cancer Res (2003) 1.65
High-b value diffusion-weighted MRI for detecting pancreatic adenocarcinoma: preliminary results. AJR Am J Roentgenol (2007) 1.54
Diffusion-weighed MR imaging of pancreatic carcinoma. Abdom Imaging (2007) 1.25
Diagnosis of suspicious breast lesions using an empirical mathematical model for dynamic contrast-enhanced MRI. Magn Reson Imaging (2006) 1.16
Monitoring breast cancer response to neoadjuvant systemic chemotherapy using parametric contrast-enhanced MRI: a pilot study. Acad Radiol (2007) 1.07
Inhibition of nuclear factor-kappaB by an antioxidant enhances paclitaxel sensitivity in ovarian carcinoma cell line. Int J Gynecol Cancer (2006) 0.98
High-resolution single-photon emission computed tomography and X-ray computed tomography imaging of Tc-99m-labeled anti-DR5 antibody in breast tumor xenografts. Mol Cancer Ther (2007) 0.95
Magnetic resonance elastography and diffusion-weighted imaging of the sol/gel phase transition in agarose. J Magn Reson (2004) 0.91
High-dose chemotherapy: how resistant is breast cancer? Drug Resist Updat (1998) 0.83
[Early prediction of response to primary chemotherapy by sequential FDG -PET in patients with advanced breast cancer]. Nihon Rinsho (2007) 0.82
Plant species richness and ecosystem multifunctionality in global drylands. Science (2012) 5.57
Live dynamic imaging of caveolae pumping targeted antibody rapidly and specifically across endothelium in the lung. Nat Biotechnol (2007) 3.54
Epitaxial core-shell and core-multishell nanowire heterostructures. Nature (2002) 3.39
Murine mammary carcinoma exosomes promote tumor growth by suppression of NK cell function. J Immunol (2006) 3.12
SIRT1 is significantly elevated in mouse and human prostate cancer. Cancer Res (2007) 2.98
Return of research results from genomic biobanks: cost matters. Genet Med (2012) 2.93
Modern age pathology of pulmonary arterial hypertension. Am J Respir Crit Care Med (2012) 2.68
Induction of myeloid-derived suppressor cells by tumor exosomes. Int J Cancer (2009) 2.64
Outcome differences after endoscopic drainage of pancreatic necrosis, acute pancreatic pseudocysts, and chronic pancreatic pseudocysts. Gastrointest Endosc (2002) 2.55
Decoupling of soil nutrient cycles as a function of aridity in global drylands. Nature (2013) 2.50
SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer. Clin Chem (2007) 2.38
Expansion of spleen myeloid suppressor cells represses NK cell cytotoxicity in tumor-bearing host. Blood (2007) 2.35
Standard operating procedures for serum and plasma collection: early detection research network consensus statement standard operating procedure integration working group. J Proteome Res (2009) 2.33
Inhibition of the catalytic function of activation-induced cytidine deaminase promotes apoptosis of germinal center B cells in BXD2 mice. Arthritis Rheum (2011) 2.33
Practical implementation issues and challenges for biobanks in the return of individual research results. Genet Med (2012) 2.32
Triptolide induces pancreatic cancer cell death via inhibition of heat shock protein 70. Cancer Res (2007) 2.27
Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias. Clin Chem (2007) 2.23
Tumor exosomes inhibit differentiation of bone marrow dendritic cells. J Immunol (2007) 2.16
Nuclear localization of KLF4 is associated with an aggressive phenotype in early-stage breast cancer. Clin Cancer Res (2004) 2.02
Promoter hypermethylation profile of kidney cancer. Clin Cancer Res (2004) 2.02
CXCL12-CXCR4 interactions modulate prostate cancer cell migration, metalloproteinase expression and invasion. Lab Invest (2004) 2.01
Characterization and functionality of cardiac progenitor cells in congenital heart patients. Circulation (2011) 1.99
Serum biomarker panels for the detection of pancreatic cancer. Clin Cancer Res (2011) 1.98
Identification of specific foods responsible for inflammation in children with eosinophilic esophagitis successfully treated with empiric elimination diet. J Pediatr Gastroenterol Nutr (2011) 1.93
Novel oligosaccharide side chains of the collagen-like region of BclA, the major glycoprotein of the Bacillus anthracis exosporium. J Biol Chem (2004) 1.92
Effects of nonsteroidal anti-inflammatory agents (NSAIDs) on ovarian carcinoma cell lines: preclinical evaluation of NSAIDs as chemopreventive agents. Clin Cancer Res (2002) 1.89
Antibody responses of variable lymphocyte receptors in the lamprey. Nat Immunol (2008) 1.87
A functional anatomic defect of the cystic fibrosis airway. Am J Respir Crit Care Med (2014) 1.85
Exosomes and cancer: a newly described pathway of immune suppression. Clin Cancer Res (2011) 1.83
Postsurgical disparity in survival between African Americans and Caucasians with colonic adenocarcinoma. Cancer (2004) 1.78
Thymus exosomes-like particles induce regulatory T cells. J Immunol (2008) 1.73
Nanowire crossbar arrays as address decoders for integrated nanosystems. Science (2003) 1.72
Multiple gene expression analyses in paraffin-embedded tissues by TaqMan low-density array: Application to hedgehog and Wnt pathway analysis in ovarian endometrioid adenocarcinoma. J Mol Diagn (2006) 1.70
Expression of sperm protein 17 (Sp17) in ovarian cancer. Int J Cancer (2004) 1.70
Preclinical comparison of near-infrared-labeled cetuximab and panitumumab for optical imaging of head and neck squamous cell carcinoma. Mol Imaging Biol (2013) 1.67
LIM kinase 1 is essential for the invasive growth of prostate epithelial cells: implications in prostate cancer. J Biol Chem (2003) 1.66
Inactivation of Smad4 accelerates Kras(G12D)-mediated pancreatic neoplasia. Cancer Res (2007) 1.66
Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model. Clin Cancer Res (2003) 1.65
In vivo molecular chemotherapy and noninvasive imaging with an infectivity-enhanced adenovirus. J Natl Cancer Inst (2002) 1.61
Direct heteroepitaxy of vertical InAs nanowires on Si substrates for broad band photovoltaics and photodetection. Nano Lett (2009) 1.60
Breast cancer chemoprevention phase I evaluation of biomarker modulation by arzoxifene, a third generation selective estrogen receptor modulator. Clin Cancer Res (2004) 1.58
Stereomicroscopic fluorescence imaging of head and neck cancer xenografts targeting CD147. Cancer Biol Ther (2008) 1.57
Predictive power of serum cystatin C to detect acute kidney injury and pediatric-modified RIFLE class in children undergoing cardiac surgery. Pediatr Crit Care Med (2012) 1.57
Method for quantitative study of airway functional microanatomy using micro-optical coherence tomography. PLoS One (2013) 1.56
Reversed diastolic flow in the renal transplant: perioperative implications versus transplants older than 1 month. AJR Am J Roentgenol (2008) 1.53
Use of fluorescent labeled anti-epidermal growth factor receptor antibody to image head and neck squamous cell carcinoma xenografts. Mol Cancer Ther (2007) 1.52
Mycophenolate mofetil: a possible therapeutic agent for children with juvenile dermatomyositis. Arthritis Care Res (Hoboken) (2010) 1.48
Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus. Mol Ther (2003) 1.43
Adipose tissue exosome-like vesicles mediate activation of macrophage-induced insulin resistance. Diabetes (2009) 1.42
Fluorescent labeled anti-EGFR antibody for identification of regional and distant metastasis in a preclinical xenograft model. Head Neck (2008) 1.42
A framework for biobank sustainability. Biopreserv Biobank (2014) 1.41
Prevention of diabetic nephropathy in Ins2(+/)⁻(AkitaJ) mice by the mitochondria-targeted therapy MitoQ. Biochem J (2010) 1.40
MicroRNA-150 directly targets MUC4 and suppresses growth and malignant behavior of pancreatic cancer cells. Carcinogenesis (2011) 1.39
Biomarkers in Diagnosis of pancreatic carcinoma in fine-needle aspirates. Am J Clin Pathol (2006) 1.39
Runx2-upregulated receptor activator of nuclear factor κB ligand in calcifying smooth muscle cells promotes migration and osteoclastic differentiation of macrophages. Arterioscler Thromb Vasc Biol (2011) 1.34
Immature myeloid cells induced by a high-fat diet contribute to liver inflammation. Hepatology (2009) 1.33
Fc gamma Rs modulate cytotoxicity of anti-Fas antibodies: implications for agonistic antibody-based therapeutics. J Immunol (2003) 1.33
Rational synthesis of p-type zinc oxide nanowire arrays using simple chemical vapor deposition. Nano Lett (2007) 1.30
Overexpression of activation-induced cytidine deaminase in B cells is associated with production of highly pathogenic autoantibodies. J Immunol (2007) 1.30
Serum levels of an isoform of apolipoprotein A-II as a potential marker for prostate cancer. Clin Cancer Res (2005) 1.30
Use of panitumumab-IRDye800 to image microscopic head and neck cancer in an orthotopic surgical model. Ann Surg Oncol (2012) 1.30
Expression and functional role of CCR9 in prostate cancer cell migration and invasion. Clin Cancer Res (2004) 1.29
Treatment of pancreatic cancer xenografts with Erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation. Int J Radiat Oncol Biol Phys (2002) 1.28
Regulation of p53 by TopBP1: a potential mechanism for p53 inactivation in cancer. Mol Cell Biol (2009) 1.28
Bax expression is a candidate prognostic and predictive marker of colorectal cancer. J Gastrointest Oncol (2010) 1.24
Pulmonary angiogenesis in a rat model of hepatopulmonary syndrome. Gastroenterology (2008) 1.23
Nanowire photodetectors. J Nanosci Nanotechnol (2010) 1.23
Expression of extracellular matrix metalloprotease inducer in laryngeal squamous cell carcinoma. Laryngoscope (2003) 1.22
Precise semiconductor nanowire placement through dielectrophoresis. Nano Lett (2009) 1.21
A phase I study of a tropism-modified conditionally replicative adenovirus for recurrent malignant gynecologic diseases. Clin Cancer Res (2010) 1.21
Activation of the neuregulin-1/ErbB signaling pathway promotes the proliferation of neoplastic Schwann cells in human malignant peripheral nerve sheath tumors. Oncogene (2005) 1.21
The role of endothelin-1 and the endothelin B receptor in the pathogenesis of hepatopulmonary syndrome in the rat. Hepatology (2004) 1.21
Myosin light chain phosphorylation is critical for adaptation to cardiac stress. Circulation (2012) 1.19
A triple-targeted ultrasound contrast agent provides improved localization to tumor vasculature. J Ultrasound Med (2011) 1.19
TRA-8 anti-DR5 monoclonal antibody and gemcitabine induce apoptosis and inhibit radiologically validated orthotopic pancreatic tumor growth. Mol Cancer Ther (2007) 1.18
Early therapy evaluation of combined anti-death receptor 5 antibody and gemcitabine in orthotopic pancreatic tumor xenografts by diffusion-weighted magnetic resonance imaging. Cancer Res (2008) 1.17
Analysis of pulmonary heme oxygenase-1 and nitric oxide synthase alterations in experimental hepatopulmonary syndrome. Gastroenterology (2003) 1.16
Combination treatment with TRA-8 anti death receptor 5 antibody and CPT-11 induces tumor regression in an orthotopic model of pancreatic cancer. Clin Cancer Res (2007) 1.14
Age-related increase of tumor susceptibility is associated with myeloid-derived suppressor cell mediated suppression of T cell cytotoxicity in recombinant inbred BXD12 mice. Mech Ageing Dev (2007) 1.14
Hormone receptors and proliferation in breast carcinomas of equivalent histologic grades in pre- and postmenopausal women. Int J Cancer (2002) 1.14